Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk

Howard D. Hosgood, Dalsu Baris, Yawei Zhang, Sonja I. Berndt, Idan Menashe, Lindsay M. Morton, Kyoung Mu Lee, Meredith Yeager, Shelia H. Zahm, Stephen Chanock, Tongzhang Zheng, Qing Lan

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Genetic variation may be an important risk factor for multiple myeloma. A hallmark of tumor formation and growth is cell cycle dysregulation and apoptosis avoidance. We previously reported the association of genetic variation in caspase genes, the apoptotic-regulating family, and multiple myeloma risk. To further examine if genetic variation in key cell cycle and apoptosis genes alters multiple myeloma risk, we genotyped 276 tag SNPs in 27 gene regions in a population-based case-control study of non-Hispanic Caucasian women (108 cases; 482 controls) in Connecticut. Logistic regression assessed the effect of each SNP on multiple myeloma risk and the minP test assessed the association at the gene region level. Three gene regions were significantly associated with risk of multiple myeloma (BAX minP = 0.018, CASP9 minP = 0.025, and RIPK1 minP = 0.037). Further explorations identified the most significant variant of BAX, RIPK1, and CASP9 to be rs1042265, rs9391981, and rs751643, respectively. The A variant at rs1042265 (ORGA+AA = 0.40, 95% CI = 0.21-0.78) and the C variant at rs9391981 (ORGC+CC = 0.32, 95% CI = 0.12-0.81) were associated with a decreased risk of multiple myeloma. The G variant at rs7516435 was associated with an increased risk of multiple myeloma (ORAG = 1.48, 95% CI = 0.94-2.32; ORGG = 2.59, 95% CI = 1.30-5.15; ptrend = 0.005). Haplotype analyses supported the SNP findings. These findings suggest that genetic variation in cell cycle and apoptosis genes may play a key role in multiple myeloma and warrant further investigation through replication studies.

Original languageEnglish (US)
Pages (from-to)1609-1614
Number of pages6
JournalLeukemia Research
Volume33
Issue number12
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Multiple Myeloma
Cell Cycle
Apoptosis
Genes
Single Nucleotide Polymorphism
cdc Genes
Caspases
Haplotypes
Case-Control Studies
Logistic Models
Growth
Population
Neoplasms

Keywords

  • BAX
  • Caspase
  • Cell cycle
  • Multiple myeloma
  • RIPK1

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Hosgood, H. D., Baris, D., Zhang, Y., Berndt, S. I., Menashe, I., Morton, L. M., ... Lan, Q. (2009). Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leukemia Research, 33(12), 1609-1614. https://doi.org/10.1016/j.leukres.2009.03.013

Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. / Hosgood, Howard D.; Baris, Dalsu; Zhang, Yawei; Berndt, Sonja I.; Menashe, Idan; Morton, Lindsay M.; Lee, Kyoung Mu; Yeager, Meredith; Zahm, Shelia H.; Chanock, Stephen; Zheng, Tongzhang; Lan, Qing.

In: Leukemia Research, Vol. 33, No. 12, 12.2009, p. 1609-1614.

Research output: Contribution to journalArticle

Hosgood, HD, Baris, D, Zhang, Y, Berndt, SI, Menashe, I, Morton, LM, Lee, KM, Yeager, M, Zahm, SH, Chanock, S, Zheng, T & Lan, Q 2009, 'Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk', Leukemia Research, vol. 33, no. 12, pp. 1609-1614. https://doi.org/10.1016/j.leukres.2009.03.013
Hosgood, Howard D. ; Baris, Dalsu ; Zhang, Yawei ; Berndt, Sonja I. ; Menashe, Idan ; Morton, Lindsay M. ; Lee, Kyoung Mu ; Yeager, Meredith ; Zahm, Shelia H. ; Chanock, Stephen ; Zheng, Tongzhang ; Lan, Qing. / Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. In: Leukemia Research. 2009 ; Vol. 33, No. 12. pp. 1609-1614.
@article{92ecc1bfe6a049d2997da46c32068560,
title = "Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk",
abstract = "Genetic variation may be an important risk factor for multiple myeloma. A hallmark of tumor formation and growth is cell cycle dysregulation and apoptosis avoidance. We previously reported the association of genetic variation in caspase genes, the apoptotic-regulating family, and multiple myeloma risk. To further examine if genetic variation in key cell cycle and apoptosis genes alters multiple myeloma risk, we genotyped 276 tag SNPs in 27 gene regions in a population-based case-control study of non-Hispanic Caucasian women (108 cases; 482 controls) in Connecticut. Logistic regression assessed the effect of each SNP on multiple myeloma risk and the minP test assessed the association at the gene region level. Three gene regions were significantly associated with risk of multiple myeloma (BAX minP = 0.018, CASP9 minP = 0.025, and RIPK1 minP = 0.037). Further explorations identified the most significant variant of BAX, RIPK1, and CASP9 to be rs1042265, rs9391981, and rs751643, respectively. The A variant at rs1042265 (ORGA+AA = 0.40, 95{\%} CI = 0.21-0.78) and the C variant at rs9391981 (ORGC+CC = 0.32, 95{\%} CI = 0.12-0.81) were associated with a decreased risk of multiple myeloma. The G variant at rs7516435 was associated with an increased risk of multiple myeloma (ORAG = 1.48, 95{\%} CI = 0.94-2.32; ORGG = 2.59, 95{\%} CI = 1.30-5.15; ptrend = 0.005). Haplotype analyses supported the SNP findings. These findings suggest that genetic variation in cell cycle and apoptosis genes may play a key role in multiple myeloma and warrant further investigation through replication studies.",
keywords = "BAX, Caspase, Cell cycle, Multiple myeloma, RIPK1",
author = "Hosgood, {Howard D.} and Dalsu Baris and Yawei Zhang and Berndt, {Sonja I.} and Idan Menashe and Morton, {Lindsay M.} and Lee, {Kyoung Mu} and Meredith Yeager and Zahm, {Shelia H.} and Stephen Chanock and Tongzhang Zheng and Qing Lan",
year = "2009",
month = "12",
doi = "10.1016/j.leukres.2009.03.013",
language = "English (US)",
volume = "33",
pages = "1609--1614",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "12",

}

TY - JOUR

T1 - Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk

AU - Hosgood, Howard D.

AU - Baris, Dalsu

AU - Zhang, Yawei

AU - Berndt, Sonja I.

AU - Menashe, Idan

AU - Morton, Lindsay M.

AU - Lee, Kyoung Mu

AU - Yeager, Meredith

AU - Zahm, Shelia H.

AU - Chanock, Stephen

AU - Zheng, Tongzhang

AU - Lan, Qing

PY - 2009/12

Y1 - 2009/12

N2 - Genetic variation may be an important risk factor for multiple myeloma. A hallmark of tumor formation and growth is cell cycle dysregulation and apoptosis avoidance. We previously reported the association of genetic variation in caspase genes, the apoptotic-regulating family, and multiple myeloma risk. To further examine if genetic variation in key cell cycle and apoptosis genes alters multiple myeloma risk, we genotyped 276 tag SNPs in 27 gene regions in a population-based case-control study of non-Hispanic Caucasian women (108 cases; 482 controls) in Connecticut. Logistic regression assessed the effect of each SNP on multiple myeloma risk and the minP test assessed the association at the gene region level. Three gene regions were significantly associated with risk of multiple myeloma (BAX minP = 0.018, CASP9 minP = 0.025, and RIPK1 minP = 0.037). Further explorations identified the most significant variant of BAX, RIPK1, and CASP9 to be rs1042265, rs9391981, and rs751643, respectively. The A variant at rs1042265 (ORGA+AA = 0.40, 95% CI = 0.21-0.78) and the C variant at rs9391981 (ORGC+CC = 0.32, 95% CI = 0.12-0.81) were associated with a decreased risk of multiple myeloma. The G variant at rs7516435 was associated with an increased risk of multiple myeloma (ORAG = 1.48, 95% CI = 0.94-2.32; ORGG = 2.59, 95% CI = 1.30-5.15; ptrend = 0.005). Haplotype analyses supported the SNP findings. These findings suggest that genetic variation in cell cycle and apoptosis genes may play a key role in multiple myeloma and warrant further investigation through replication studies.

AB - Genetic variation may be an important risk factor for multiple myeloma. A hallmark of tumor formation and growth is cell cycle dysregulation and apoptosis avoidance. We previously reported the association of genetic variation in caspase genes, the apoptotic-regulating family, and multiple myeloma risk. To further examine if genetic variation in key cell cycle and apoptosis genes alters multiple myeloma risk, we genotyped 276 tag SNPs in 27 gene regions in a population-based case-control study of non-Hispanic Caucasian women (108 cases; 482 controls) in Connecticut. Logistic regression assessed the effect of each SNP on multiple myeloma risk and the minP test assessed the association at the gene region level. Three gene regions were significantly associated with risk of multiple myeloma (BAX minP = 0.018, CASP9 minP = 0.025, and RIPK1 minP = 0.037). Further explorations identified the most significant variant of BAX, RIPK1, and CASP9 to be rs1042265, rs9391981, and rs751643, respectively. The A variant at rs1042265 (ORGA+AA = 0.40, 95% CI = 0.21-0.78) and the C variant at rs9391981 (ORGC+CC = 0.32, 95% CI = 0.12-0.81) were associated with a decreased risk of multiple myeloma. The G variant at rs7516435 was associated with an increased risk of multiple myeloma (ORAG = 1.48, 95% CI = 0.94-2.32; ORGG = 2.59, 95% CI = 1.30-5.15; ptrend = 0.005). Haplotype analyses supported the SNP findings. These findings suggest that genetic variation in cell cycle and apoptosis genes may play a key role in multiple myeloma and warrant further investigation through replication studies.

KW - BAX

KW - Caspase

KW - Cell cycle

KW - Multiple myeloma

KW - RIPK1

UR - http://www.scopus.com/inward/record.url?scp=70349170571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349170571&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2009.03.013

DO - 10.1016/j.leukres.2009.03.013

M3 - Article

C2 - 19362737

AN - SCOPUS:70349170571

VL - 33

SP - 1609

EP - 1614

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 12

ER -